

Imdevimab

Catalogue No.: abx376500

This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD Neutralizing Antibody (Imdevimab) is a research grade recombinant Human Monoclonal Antibody biosimilar expressed in CHO cells, against SARS-CoV-2/COVID-19 Spike Protein RBD.

The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.

Target:	SARS-CoV-2 Spike Protein RBD
Research Area:	Biosimilars
Clonality:	Monoclonal
Clone:	REGN10987
Reactivity:	Virus
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions:	ELISA: 1/5000 - 1/10000, WB: 1/1000 - 1/2000. Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Immunogen:	Recombinant SARS-CoV-2 RBD protein
Isotype:	IgG
Form:	Liquid
Purification:	Purified by affinity chromatography.

Datasheet

Version: 3.0.0
Revision date: 29 Jan 2026



Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

Buffer: PBS, pH 7.5.

Specificity: Recognizes SARS-CoV-2 RBD Protein

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

For Reference Only